1,25-dihydroxyvitamin D-mediated hypercalcemia in a renal transplant recipient.
Hypercalcemia occurs in 10 to 30% of renal transplant recipients and is most often due to persistent hyperparathyroidism. Herein we describe a patient with a history of hyperparathyroidism who sought medical assessment because of recurrence of hypercalcemia 7 years after a successful renal transplantation. The hypercalcemia was associated with a normal serum phosphate level, a low to normal parathyroid hormone level, virtually undetectable levels of parathyroid hormone-related protein, and increased 1,25-dihydroxyvitamin D levels. Further assessment led to the diagnosis of an underlying lymphoma. To our knowledge, this is the first report of 1,25-dihydroxyvitamin D-mediated hypercalcemia in a renal transplant recipient with lymphoma. The possibility of an underlying lymphoproliferative disorder should be considered in the differential diagnosis of hypercalcemia in a renal transplant recipient.
Golconda
M S
MS
Division of Nephrology and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.
Larson
T S
TS
Kolb
L G
LG
Kumar
R
R
D002117:Calcitriol / Q000097:blood*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000209:etiology*; D016030:Kidney Transplantation; D008223:Lymphoma / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D008875:Middle Aged
D002117:Calcitriol